Completed PHASE1 INTERVENTIONAL 1-arm NCT00207090

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Sponsor: R-Pharm

Conditions Advanced Solid Tumors Neoplasms

Updated 7 times since 2017 Last updated: Oct 6, 2020 Started: Sep 30, 2005 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and Neoplasms and is currently completed. R-Pharm leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2020 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States